Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

K Matthay

Showing results (211-220 of 316) with videos related to

Pageof 32
Sort By:
Research Square|February 5, 2024
Aurora Kinase A inhibition enhances DNA damage and tumor cell death with <sup>131</sup>I-MIBG therapy in high-risk neuroblastomaPrerna Kumar, Jessica Koach, Erin Nekritz, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 20, 2011
Clinical and biologic features predictive of survival after relapse of neuroblastoma: a report from the International Neuroblastoma Risk Group projectWendy B London, Victoria Castel, Tom Monclair, et al.
International Journal of Radiation Oncology, Biology, Physics|May 5, 2009
Successful treatment of high risk and recurrent pediatric desmoids using radiation as a component of multimodality therapySiavash Jabbari, David Andolino, Vivian Weinberg, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 1, 1994
Allogeneic versus autologous purged bone marrow transplantation for neuroblastoma: a report from the Childrens Cancer GroupK K Matthay, R C Seeger, C P Reynolds, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 21, 2007
Phase II study on the effect of disease sites, age, and prior therapy on response to iodine-131-metaiodobenzylguanidine therapy in refractory neuroblastomaKatherine K Matthay, Gregory Yanik, Julia Messina, et al.
Pediatric Blood & Cancer|January 20, 2018
Predictors of response, progression-free survival, and overall survival using NANT Response Criteria (v1.0) in relapsed and refractory high-risk neuroblastomaJudith G Villablanca, Lingyun Ji, Adi Shapira-Lewinson, et al.
Journal of Cellular Biochemistry|May 9, 2007
Nordihydroguaiaretic acid inhibits insulin-like growth factor signaling, growth, and survival in human neuroblastoma cellsGary E Meyer, Louis Chesler, Dandan Liu, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 7, 2009
Comparison of iodine-123 metaiodobenzylguanidine (MIBG) scan and [18F]fluorodeoxyglucose positron emission tomography to evaluate response after iodine-131 MIBG therapy for relapsed neuroblastomaDenah R Taggart, Myo M Han, Alekist Quach, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 17, 2002
Pilot study of iodine-131-metaiodobenzylguanidine in combination with myeloablative chemotherapy and autologous stem-cell support for the treatment of neuroblastomaGregory A Yanik, John E Levine, Katherine K Matthay, et al.
International Journal of Cancer. Supplement = Journal International Du Cancer. Supplement|February 19, 2000
Somatization, anxiety and depression as measures of health-related quality of life of children/adolescents with cancerJ M Challinor, C A Miaskowski, L S Franck, et al.
Pageof 32

Showing results (211-220 of 316) with videos related to

Sort By:
Pageof 32
Research Square|February 5, 2024
Aurora Kinase A inhibition enhances DNA damage and tumor cell death with <sup>131</sup>I-MIBG therapy in high-risk neuroblastomaPrerna Kumar, Jessica Koach, Erin Nekritz, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 20, 2011
Clinical and biologic features predictive of survival after relapse of neuroblastoma: a report from the International Neuroblastoma Risk Group projectWendy B London, Victoria Castel, Tom Monclair, et al.
International Journal of Radiation Oncology, Biology, Physics|May 5, 2009
Successful treatment of high risk and recurrent pediatric desmoids using radiation as a component of multimodality therapySiavash Jabbari, David Andolino, Vivian Weinberg, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 1, 1994
Allogeneic versus autologous purged bone marrow transplantation for neuroblastoma: a report from the Childrens Cancer GroupK K Matthay, R C Seeger, C P Reynolds, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 21, 2007
Phase II study on the effect of disease sites, age, and prior therapy on response to iodine-131-metaiodobenzylguanidine therapy in refractory neuroblastomaKatherine K Matthay, Gregory Yanik, Julia Messina, et al.
Pediatric Blood & Cancer|January 20, 2018
Predictors of response, progression-free survival, and overall survival using NANT Response Criteria (v1.0) in relapsed and refractory high-risk neuroblastomaJudith G Villablanca, Lingyun Ji, Adi Shapira-Lewinson, et al.
Journal of Cellular Biochemistry|May 9, 2007
Nordihydroguaiaretic acid inhibits insulin-like growth factor signaling, growth, and survival in human neuroblastoma cellsGary E Meyer, Louis Chesler, Dandan Liu, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 7, 2009
Comparison of iodine-123 metaiodobenzylguanidine (MIBG) scan and [18F]fluorodeoxyglucose positron emission tomography to evaluate response after iodine-131 MIBG therapy for relapsed neuroblastomaDenah R Taggart, Myo M Han, Alekist Quach, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 17, 2002
Pilot study of iodine-131-metaiodobenzylguanidine in combination with myeloablative chemotherapy and autologous stem-cell support for the treatment of neuroblastomaGregory A Yanik, John E Levine, Katherine K Matthay, et al.
International Journal of Cancer. Supplement = Journal International Du Cancer. Supplement|February 19, 2000
Somatization, anxiety and depression as measures of health-related quality of life of children/adolescents with cancerJ M Challinor, C A Miaskowski, L S Franck, et al.
Pageof 32